Related Experiment Videos
Overexpression of the MDM2 oncogene in leukemia and lymphoma
T Watanabe1, A Ichikawa, H Saito
1First Department of Internal Medicine, Nagoya University School of Medicine, Japan.
Abstract:
A cellular phosphoprotein that binds to and inactivates p53 has recently been identified as a product of the oncogene MDM2. Amplification of the MDM2 gene was found in more than a third of sarcomas and in a subset of malignant gliomas. Despite the absence of amplification, the MDM2 gene was overexpressed in some types of leukemias and lymphomas. Overexpression was significantly more frequent in the low-grade type of B-cell non-Hodgkin's lymphoma (B-NHL) than in the intermediate/high grade types of lymphoma and the overexpression was also significantly more frequent in the advanced rather than the earlier stages of B-cell chronic lymphocytic leukemia (B-CLL) and B-NHL. This suggests that MDM2 could play a role, via the p53 pathway, in tumorigenicity and/or in disease progression in some hematological malignancies. However, in the light of our findings that, in a few cases, both the overexpression of MDM2 and mutant-type p53 was seen, it is possible that MDM2 overexpression may also promote neoplastic growth by mechanisms other than inactivation of the p53 protein.
Insights
The oncogene MDM2 inactivates the tumor suppressor p53. MDM2 gene amplification and overexpression are linked to various cancers, including lymphomas and leukemias, suggesting a role in disease progression.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MDM2 is an oncogene product that binds and inactivates the tumor suppressor p53.
- MDM2 gene amplification is observed in sarcomas and malignant gliomas.
- MDM2 gene is overexpressed in certain leukemias and lymphomas.
Purpose of the Study:
- To investigate the role of MDM2 gene amplification and overexpression in hematological malignancies.
- To explore the association between MDM2 and p53 in tumorigenesis and disease progression.
Main Methods:
- Analysis of MDM2 gene amplification in sarcomas and gliomas.
- Assessment of MDM2 gene expression in various hematological malignancies, including B-cell non-Hodgkin's lymphoma (B-NHL) and B-cell chronic lymphocytic leukemia (B-CLL).
- Evaluation of p53 status in conjunction with MDM2 overexpression.
Main Results:
- MDM2 gene amplification found in over a third of sarcomas and some malignant gliomas.
- MDM2 overexpression observed in leukemias and lymphomas, notably more frequent in low-grade B-NHL and advanced stages of B-CLL and B-NHL.
- Co-occurrence of MDM2 overexpression and mutant p53 in a subset of cases.
Conclusions:
- MDM2 may contribute to tumorigenicity and progression in hematological malignancies through the p53 pathway.
- MDM2 overexpression might promote cancer growth via p53-independent mechanisms, as suggested by cases with both MDM2 overexpression and mutant p53.